Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.38 |
| ▸ | ITGAL | P20701 | 3/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21433947 | 0.90 | FAAH (0.45) | FAAHTRPA1EPHX2KMOCHRM4 | |
| SCHEMBL21434105 | 0.90 | EPHX2 (0.44) | FAAHTRPA1EPHX2KMOITGB2 | |
| SCHEMBL21434171 | 0.89 | EPHX2 (0.47) | FAAHTRPA1EPHX2KMOITGB2 | |
| SCHEMBL21434087 | 0.87 | EPHX2 (0.49) | FAAHTRPA1EPHX2KMOITGB2 | |
| SCHEMBL21434000 | 0.84 | ITGB2 (0.51) | FAAHTRPA1EPHX2KMOITGB2 | |
| SCHEMBL21434100 | 0.84 | EPHX2 (0.48) | FAAHTRPA1EPHX2KMOCHRM4 | |
| SCHEMBL21433934 | 0.83 | EPHX2 (0.45) | FAAHTRPA1EPHX2KMOITGB2 | |
| SCHEMBL21433925 | 0.81 | ITGB2 (0.48) | FAAHTRPA1EPHX2ITGB2ICAM1 | |
| SCHEMBL21434160 | 0.81 | FAAH (0.46) | FAAHTRPA1EPHX2KMOITGB2 | |
| SCHEMBL21434028 | 0.80 | CHRM2 (0.47) | FAAHTRPA1CHRM4ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-18 | — | — | US | disclosed |
| EP-3774732-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019193516-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | WO | disclosed |
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | FAAH 3070/4885TRPA1 790/4885EPHX2 2087/4885 |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | FAAH 3070/4885TRPA1 790/4885EPHX2 2087/4885 |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3B | FAAH 2955/4885TRPA1 875/4885EPHX2 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.